Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alaunos Therapeutics, Inc. (TCRT)

Alaunos Therapeutics regains Nasdaq stockholders' equity compliance; delisting hearing canceled

Positive Impact 3 of 5 legal/regulatory Written later

Alaunos Therapeutics said Nasdaq confirmed it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, closing the matter and canceling the November 10, 2026 hearing before the Nasdaq Hearings Panel. Its common stock will continue to be listed and traded on The Nasdaq Capital Market, removing the near-term delisting risk for shareholders.

Key points

  • Nasdaq notified the company on April 9, 2026 that it was not in compliance with the $2,500,000 stockholders' equity requirement.
  • The company said a private placement completed on October 14, 2026 led it to believe it had regained compliance.
  • On October 22, 2026, Nasdaq's Office of General Counsel confirmed compliance and closed the matter.
  • The hearing scheduled for November 10, 2026 was cancelled.

The filing

CompanyAlaunos Therapeutics, Inc. (TCRT)
Form8-K, current report
Filed with the SECOct 23, 2026, 4:30 PM ET
Accession number0001193125-26-430507

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.